C
CATALYST PHARMACEUTICALS, INC.
Period
FY 2025
Revenue
$588.99M
Net Income
$214.33M
Total Assets
—
Equity
—
Shares Out
122.38M
Op. Cash Flow
$208.67M
Business
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company that in-licenses, develops, and commercializes novel medicines for patients with rare and difficult-to-treat diseases. The company markets three FDA-approved products: FIRDAPSE® (amifampridine) for Lambert-Eaton Myasthenic Syndrome, AGAMREE® (vamorolone) for Duchenne muscular dystrophy, and FYCOMPA® (perampanel) for certain types of epilepsy. The company operates primarily in the U.S. market through direct field-based sales forces and specialty pharmacy distribution networks, with international presence in Canada and Japan for select products.
Summary from 10-K filed 2026-02-25
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total revenues | 589 | 492 | 398 | 214 | 141 | |
| Cost of sales | 87 | 69 | 52 | 34 | 22 | |
| Research and development | 13 | 13 | 93 | 20 | 17 | |
| Selling, general and administrative | 194 | 178 | 134 | 57 | 50 | |
| Amortization of intangible assets | 37 | 37 | 33 | 1 | 0 | |
| Total operating costs and expenses | 331 | 297 | 311 | 112 | 88 | |
| Operating income | 258 | 195 | 87 | 102 | 52 | |
| Other income, net | 26 | 21 | 8 | 3 | 282,000 | |
| Net income before income taxes | 284 | 216 | 95 | 105 | 53 | |
| Income tax provision | 69 | 52 | 23 | 22 | 13 | |
| Net income | 214 | 164 | 71 | 83 | 39 | |
| Basic (per share) | 1.75 | 1.38 | 0.67 | 0.8 | 0.38 | |
| Diluted (per share) | 1.68 | 1.31 | 0.63 | 0.75 | 0.37 | |
| Basic (shares) | 122 | 118 | 106 | 103 | 103 | |
| Diluted (shares) | 127 | 125 | 114 | 111 | 108 | |
| Unrealized gain (loss) on available-for-sale securities, net of tax of $0, ($20) and $4, respectively | −64,000 | 50,000 | −10,000 | 172,000 | −179,000 | |
| Comprehensive income | 214 | 164 | 71 | 83 | 39 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 709 | 518 | 138 | 298 | 171 | |
| Accounts receivable, net | 126 | 65 | 54 | 10 | 7 | |
| Inventory, net | 37 | 20 | 16 | 7 | 8 | |
| Prepaid expenses and other current assets | 21 | 21 | 13 | 5 | 4 | |
| Total current assets | 894 | 624 | 219 | 321 | 210 | |
| Operating lease right-of-use asset, net | 2 | 2 | 3 | 3 | 3 | |
| Property and equipment, net | 1 | 1 | 1 | 847,000 | 959,000 | |
| License and acquired intangibles, net | 132 | 157 | 194 | 32 | — | |
| Deferred tax assets, net | 53 | 46 | 37 | 19 | 24 | |
| Investment in equity securities | 23 | 22 | 16 | 0 | — | |
| Total assets | 1,104 | 851 | 470 | 376 | 238 | |
| Accounts payable | 11 | 17 | 15 | 4 | 3 | |
| Accrued expenses and other liabilities | 136 | 104 | 61 | 54 | 24 | |
| Total current liabilities | 147 | 121 | 76 | 58 | 27 | |
| Operating lease liability, net of current portion | 2 | 3 | 3 | 4 | 4 | |
| Other non-current liabilities | 209,000 | 315,000 | 3 | 14 | — | |
| Total liabilities | 150 | 124 | 82 | 75 | 31 | |
| Commitments and contingencies (Note 12) | — | — | — | — | — | |
| Preferred stock, $0.001 par value, 5,000,000 shares authorized: none issued and outstanding at December 31, 2025 and 2024 | 0 | 0 | 0 | 0 | 0 | |
| Common stock, $0.001 par value, 200,000,000 shares authorized; 122,513,621 shares and 120,879,099 shares issued and outstanding at December 31 2025 and 2024, respectively | 123,000 | 121,000 | 107,000 | 105,000 | 103,000 | |
| Additional paid-in capital | 480 | 442 | 266 | 250 | 233 | |
| Retained earnings | 474 | 285 | 121 | 50 | −26 | |
| Accumulated other comprehensive income (Note 4) | 0 | 64,000 | 14,000 | 24,000 | −148,000 | |
| Total stockholders' equity | 954 | 728 | 388 | 300 | 207 | |
| Total liabilities and stockholders' equity | 1,104 | 851 | 470 | 376 | 238 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net income | 214 | 164 | 71 | 83 | 39 | |
| Depreciation | 375,000 | 397,000 | 316,000 | 141,000 | 192,000 | |
| Stock-based compensation | 25 | 22 | 14 | 8 | 6 | |
| Amortization of intangible assets | 37 | 37 | 33 | 1 | 0 | |
| Deferred taxes | −7 | −9 | −18 | 5 | 9 | |
| Accretion of discount | −350,000 | −835,000 | 1 | 17,000 | −5,000 | |
| Reduction in the carrying amount of right-of-use asset | 295,000 | 278,000 | 262,000 | 247,000 | 292,000 | |
| Acquired inventory samples expensed from asset acquisition | 0 | 0 | 130,000 | 0 | — | |
| Acquired in-process research and development | 0 | 0 | 82 | 0 | — | |
| Change in fair value of equity securities | −972,000 | −5 | −3 | 0 | 0 | |
| Inventory reserve and write-offs | 464,000 | 0 | 0 | — | — | |
| Accounts receivable, net | −61 | −12 | −43 | −4 | −632,000 | |
| Inventory, net | −18 | −4 | −5 | 1 | −3 | |
| Prepaid expenses and other current assets | −177,000 | −9 | −6 | −807,000 | 4 | |
| Accounts payable | −5 | 2 | 11 | 1 | −1 | |
| Accrued expenses and other liabilities | 24 | 54 | 6 | 16 | 6 | |
| Operating lease liability | −401,000 | −369,000 | −338,000 | −307,000 | 864,000 | |
| Net cash provided by (used in) operating activities | 209 | 240 | 144 | 116 | 60 | |
| Purchases of property and equipment | −58,000 | −556,000 | −231,000 | −29,000 | −1 | |
| Payments in connection with asset acquisitions | 0 | 0 | −198 | −10 | — | |
| Acquisition of in-process research and development | 0 | 0 | −82 | 0 | — | |
| Purchase of equity securities | 0 | 0 | −13 | 0 | — | |
| Net cash provided by (used in) investing activities | −58,000 | −556,000 | −294 | 9 | −11 | |
| Payment of employee withholding tax related to stock-based compensation | −2 | −668,000 | −982,000 | −230,000 | −153,000 | |
| Proceeds from exercise of stock options | 15 | 14 | 3 | 10 | 4 | |
| Repurchase of common stock | −25 | 0 | 0 | −7 | −12 | |
| Payment of liabilities arising from asset acquisition | −5 | −13 | −13 | −738,000 | — | |
| Proceeds from issuance of common stock | 0 | 141 | 0 | — | — | |
| Payment of fees in connection with issuance of common stock | 0 | −296,000 | 0 | — | — | |
| Net cash provided by (used in) financing activities | −17 | 141 | −11 | 2 | −8 | |
| Net increase (decrease) in cash and cash equivalents | 192 | 380 | −161 | 127 | 41 | |
| Cash paid for income taxes | 72 | 68 | 50 | 8 | 3 | |
| Cash paid for interest | 466,000 | 1 | 705,000 | 0 | — | |
| Liabilities arising from asset acquisition | 0 | 0 | 2 | 28 | — | |
| Accrued milestone payment classified as license and acquired intangibles, net | 13 | 0 | 0 | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is CATALYST PHARMACEUTICALS, INC.'s CIK number?
CATALYST PHARMACEUTICALS, INC.'s SEC CIK number is 0001369568 (1369568). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find CATALYST PHARMACEUTICALS, INC.'s SEC filings?
All of CATALYST PHARMACEUTICALS, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.